Status:
TERMINATED
The Effect of Mitomycin C on Corneal Haze and Scarring After Corneal Crosslinking in Keratoconus Patients
Lead Sponsor:
Ciusss de L'Est de l'Île de Montréal
Conditions:
Keratoconus
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
Corneal crosslinking (Crosslinking, CXL) is a treatment offered for the stabilization of early corneal ectatic disorders such as keratoconus. Although CXL is an excellent treatment option to stabilize...
Eligibility Criteria
Inclusion
- Patients from both genders with confirmed keratoconus with evidence of clinical and topographic progression.
- Patients with the diagnosis of other ectatic disorders such as post refractive surgery ectasia with evidence of clinical and topographic progression.
Exclusion
- Patients who are pregnant
- Patients who are breast-feeding
- Patients who have allergy to MMC
- Patients with other corneal conditions such as limbal stem cell deficiency (LSCD)
- Patients with peripheral marginal keratitis
- Patients with history of corneal melting
- Patients with history of HSV/VZV keratitis
- Patients with history of hydrops
Key Trial Info
Start Date :
July 26 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 22 2023
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT04811924
Start Date
July 26 2021
End Date
February 22 2023
Last Update
February 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada, H1T 2M4